Heart Disease and Stroke Statistics—2023 Update: A Report From ...
Google Trials Automatically Created Assets For Performance Max
Google has started testing its automatically created assets feature on Performance Max campaigns after announcing plans to do so at Google Marketing Live last month. Advertisers have reported seeing the scheme, which is available to all marketers as an open beta on Google Ads, replace the 'Final URL expansion' tab.
Why we care: Advertisers struggling to write engaging ad assets for Performance Max campaigns no longer need to worry about creative fatigue because Google can help do this job for them, saving marketers some time and effort.
How it works: Google can generate copy for Performance Max listings by analysing the content on a brand's landing pages, domain and ads.
What have digital marketers said? While the thought of never having to write ad assets again will appeal to many advertisers, some industry insiders have warned that there are potential risks.
Get the daily newsletter search marketers rely on.
What has Google said? Brands that have opted to use its automatically created assets feature for headlines and descriptions have seen enhanced performance with on average a 2% increase in conversions, Google said. Other benefits, according to Google, include:
A Google spokesperson told Search Engine Land:
Is there a catch? The main concern raised by advertisers around automatically generated assets is a reduction in creative control. Sometimes, the content created by Google doesn't accurately fit a product's brand, can be inaccurate or doesn't make sense. These issues have deterred some marketers from using the feature.
Go deeper: You can read more about Automatically Created Assets here and more Performance Max here.
14.5 Million Files Delay Trials Of Those Accused Of YDC Abuse
Judge issued order to schedule the trials, move the cases forward
Hillsborough County Superior Court Northern District Judge N. William Delker. (Photo by Jeffrey Hastings) Nearly two years after 10 former Youth Development Center employees were charged with sexually abusing youth at the state-run juvenile detention facility, trials have yet to be scheduled.
What has caused the delay in setting trial dates is more than 14.5 million digital and other files, including hand-written documents, concerning YDC and the youth allegedly abused over 13 years, from 1994 to 2007.
An order issued last week by Judge N. William Delker, presiding in Hillsborough County Superior Court Northern District where the 10 defendants will be tried, aims to move the cases along and finally schedule the trials.
In his final order regarding digital discovery, dated June 6, 2023, Delker explained New Hampshire has no rule of criminal procedure governing production of discovery in the form of electronically stored information (ESI).
"The dispute here revolves around how to make the large volume of ESI available to the defense in a manner that is practical to search and organize. The parties disagree about the best manner to accomplish that goal," he wrote.
The discovery consists of two groups: 14,595,819 digital files extracted from 96 New Hampshire Department of Health and Human Services' hard drives, called the "Harddrive Discovery."
The other group consists of 1,777,602 pages from a variety of sources, the bulk of which have been scanned (Scanned Discovery). However, the majority appear to be handwritten documents which cannot be converted to text through optical character recognition (OCR) processing.
The defense and prosecution agreed to use the state's e-discovery platform called Relativity to review and organize the Harddrive Discovery.
The judge said the State – through Shaheen Phinney – has already spent considerable time and money to cull the hard drives of irrelevant files, reducing the volume from nearly 77 million files to about 14.5 million files.
Delker said it would be a duplicative and unnecessary expense for the defense to upload the contents of the 96 hard drives to its own platform. He also said it was not feasible to extract the 14.5 million files from Relativity to be loaded on the defense's own e-discovery platform.
"Finally, to allow that volume of discovery to be stored on two separate databases would be a considerable cost with little or no added benefit to the defense's ability to prepare for trial," the judge said.
He said the defense can search, review and code or tag discovery with five top folders and an unlimited number of subfolders. "This provides the defense abundant flexibility to identify and organize the relevant files on the Harddrive Discovery without unnecessary expenditure of resources," Delker said.
The Scanned Discovery is a more difficult problem. The prosecution, Delker said, identified 12,641 files – "hot documents" — it believes are most relevant to the cases. The "hot documents" are part of the Scanned Discovery upon which the state's cases are built. However, most of the Scanned Discovery, unlike the Harddrive Discovery, is not full-text searchable.
The State added coding to 853,785 documents to help research, sort, organize and identify relevant discovery of those files. The prosecution offered the defense access to its coded documents through the Relativity database. The defense wants to review and process the Scanned Discovery on its own e-discovery platform called Casepoint.
The defense asked the court to order the state to extract the coded files from Relativity so that discovery together with the coding can be imported into Casepoint. The state objected.
The judge said if the defense is obligated to rely on the state's Relativity database, the defense team would also be required to channel all questions, requests, modifications, or other inquiries relating to Relativity through the state's chosen experts, Shaheen Phinney. He said the state conceded that the Attorney General is Sheehan Phinney's client and they maintain an attorney-client relationship with the law firm.
"The defense is certainly entitled to its own e-discovery expert to help defense counsel formulate strategies for searching and organizing the data for trial," Delker said. He also said forcing defense lawyers and their expert to go through the state's e-discovery expert as they use the Relativity platform creates a substantial risk of delay and potential for miscommunication.
"Like the state, the defense lawyers should be able to process discovery with their own expert directly on their own discovery platform without having to work through Shaheen Phinney as an intermediary," Delker said.
He ordered the state to make the Harddrive Discovery available to defense to begin searching through Relativity immediately. He approved funds for one software license for each defense team to access Relativity and will approve funds for services required of Sheehan Phinney to make the platform accessible to the defense teams.
Delker also ordered the state to produce coded files from the Scanned Discovery, to begin production as soon as feasible and provide the extracted data to the defendants' e-discovery consultant on a rolling basis as it becomes available.
The defense e-discovery consultant is to promptly upload the coded Scanned Discovery production to Casepoint.
Within 45 days, both parties are to submit proposed trial dates and deadlines for motions and expert disclosures.
The defendants in the 10 cases in Hillsborough County are authorized collectively to enter into a contract for the Casepoint e-discovery platform at a cost of $122,000.
The defendants are:
Bradley Asbury, 68, Dunbarton; Jeffrey Buskey, 56, Quincy, Mass.; Frank Davis, 81, Contoocook; Stephen Murphy, 57, Danvers, Mass.; Lucien Poulette, 67, Auburn; Gordon Thomas Searles, 67, Weare; James Woodlock, 58, Manchester; Jonathan Brand, 58, Concord; Trevor Middleton, 54, Belmont; Stanley Watson, 54, Allenstown.
This article is being shared by partners in The Granite State News Collaborative. For more information, visit collaborativenh.Org.
AWAK Technologies And Singapore General Hospital Launch Pre-pivotal Clinical Trial Of Wearable Peritoneal Dialysis Device
SINGAPORE, June 19, 2023 /PRNewswire/ -- AWAK Technologies (AWAK) and Singapore General Hospital (SGH) announce the launch of a pre-pivotal clinical trial with the enrolment of their first subject to study the safety and efficacy of an improved Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device.
AWAK PD is a wearable and ultra-portable peritoneal dialysis (PD) system that allows patients with end-stage kidney disease to have dialysis on the go and has been granted 'Breakthrough Device Designation' by the US Food and Drug Administration (FDA).
The single site, prospective, single-arm study is a follow-up of its first-in-human study which reported no serious adverse events. The team of SGH researchers is now recruiting subjects to participate in this pre-pivotal clinical trial.
Suresha Venkataraya, Chief Executive Officer, AWAK Technologies, said: "Entering the pre-pivotal trial with the enhanced version of our device signifies a significant step in our mission to revolutionize the dialysis industry. The invaluable insights and feedback from the initial first-in-human trial have been vital in refining and enhancing our product. We remain committed to redefining kidney care by bringing disruptive products to improve the quality of life of people with kidney disease. We thank our board of directors, investors, and clinical partner, Singapore General Hospital, for their unwavering support throughout our innovation journey."
Associate Professor Marjorie Foo, Principal Investigator of both AWAK PD trials and Senior Consultant, Department of Renal Medicine, SGH, said: "Although most patients with end-stage kidney disease are on haemodialysis, peritoneal dialysis offers similar efficiency and cost effectiveness with the added flexibility of treatment schedule to accommodate ones' lifestyle and offers patient another option to choose from. We have collaborated with AWAK Technologies on this project since its early years of development. Despite COVID-19 slowing us down, we have continued to improve on the device and are now ready to embark on a pre-pivotal trial, one step closer to what our patients are hoping and looking forward to, a life on dialysis that will minimally affect their lifestyle and yet provide good quality dialysis.
Media contacts
Candice Lee Communications Department Singapore General Hospital +65 9146 3107 candice.Lee.L.F@sgh.Com.Sg
About AWAK PD
AWAK PD is the world's to-be-first wearable and ultra-portable peritoneal dialysis (PD) system that incorporates AWAK's patented sorbent technology to disrupt the way in which peritoneal dialysis is currently administered. AWAK PD is a compact device that weighs around 3 kg and enables dialysis to be performed on the go, overcoming the challenge of long hours of stationary therapy and connection to large-size dialysis machines in hospitals and clinics, a challenge currently faced by patients who need dialysis.
AWAK's patented technologies not only regenerate and reconstitute waste dialysis fluid into fresh usable fluid thus reducing the amount of dialysis fluid needed by up to 90 per cent, but also enable the miniaturisation of the dialysis machine to fit into a small carry bag.
AWAK PD has undergone First-In-Human (FIH) trial following which this pre-pivotal clinical trial will test the enhanced version of the device before advancing to a pivotal trial aimed for regulatory approval and market authorization of AWAK PD.
About End-Stage Kidney Disease
End-stage Kidney Disease (ESKD) is the fifth stage of Chronic Kidney Disease (CKD) that affects the functioning of kidneys, leading to accumulation of excess fluid and toxic wastes in the blood. People with ESKD undergo either kidney transplantation or dialysis. Since kidney transplantation is highly dependent on patient's health and age, dialysis scores over as the primary treatment.
As of 2022, estimates indicate that about 4 million people with kidney failure are treated with dialysis or live with a kidney transplant worldwide. Of all dialysis, 11 per cent of the patients are on peritoneal dialysis (PD) and the remaining 89 per cent are on haemodialysis (HD).
Dialysis treatment can be performed either at home, in a dialysis centre or at a hospital. In haemodialysis, blood is drawn out of the patient's body into a synthetic filter called dialyser. In the dialyser, there are two spaces separated by a membrane, with blood passing on one side and dialysis fluid on the other side. Waste products and excess water passes from the blood through the membrane into the fluid through diffusion process. The fluid containing the waste products is then discarded while the clean blood is returned back to the patient's body.
In peritoneal dialysis, the lining of the abdominal cavity acts like the external filter to cleanse the blood. Dialysis fluid is introduced into the abdominal cavity through a permanent tube. The fluid remains in the abdominal for a certain period of time before it is drained and discarded.
About AWAK Technologies
AWAK Technologies Pte Ltd. Is a pioneering, patient-centric medical technology company with a mission to enhance the lives of people with kidney disease and their caregivers by providing solutions to deliver better outcomes and improve their quality of life.
Headquartered in Singapore with subsidiaries in Burbank (California, USA) and Bangalore (Karnataka, India), the company is dedicated to the research, development and marketing of novel solutions for the treatment of patients with kidney disease. For more information, please visit: www.Awak.Com
About Singapore General Hospital
Singapore General Hospital, established in 1821, is the largest tertiary hospital in Singapore and ranked among the world's best. It provides the most comprehensive patient-centred care with over 50 clinical specialties on its campus. As an Academic Medical Centre, it takes pride in training healthcare professionals and conducting cutting edge research to meet evolving needs of the nation as well as the region. Driven by a strong sense of purpose, SGH is committed to give of its best to heal and bring hope, as it has for over 200 years. For more information, please visit www.Sgh.Com.Sg
View original content to download multimedia:https://www.Prnewswire.Com/news-releases/awak-technologies-and-singapore-general-hospital-launch-pre-pivotal-clinical-trial-of-wearable-peritoneal-dialysis-device-301852063.Html
SOURCE AWAK Technologies
Comments
Post a Comment